Articles tagged with Drug Resistance
Research found that treatments with 6-mercaptopurine and/or 5-azacitidine do not reverse epithelial-to-mesenchymal transition, but instead sensitize cancer cells to chemotherapeutic drugs. This approach has potential for inhibiting highly resistant triple-negative breast cancer cells.
A new combination treatment targeting two proteins may improve survival for T-ALL patients who don't respond to standard chemotherapy. By inhibiting Kinase C and Notch1, researchers aim to overcome drug resistance and enhance treatment efficacy.
New data reveals that mutations in the malaria parasite Plasmodium falciparum may be gaining a foothold in Africa, linked to delayed parasite clearance. The study finds that these mutations are more prevalent than previously reported, raising concerns about further geographical spread of resistance.
Research found that ABC transporters in plants can confer glyphosate resistance by moving the herbicide out of cells. This is achieved through the EcABCC8 transporter, which was shown to exhibit higher expression levels in resistant weed species.
A study published in Clinical Cancer Research found that specific gene signatures and immune cells can predict response to immunotherapy in bladder cancer patients. The researchers identified potential biomarkers for treatment resistance and new combination therapeutic approaches to overcome such resistance.
Researchers have identified key mechanisms that enable cancer cells to resist therapies targeting mutated KRAS protein. The findings suggest a potential role for rational drug design and combination therapy in overcoming resistance.
Researchers at Radboud University Medical Center have found that a higher dose of the anti-tuberculosis drug rifampicin is safe and effective. This could lead to a shorter treatment duration and less resistance, with potential benefits for global tuberculosis treatment.
Sabrina L. Spencer, a CU Boulder researcher, has won two awards to further her research on drug-resistant cancer cells. The grants will help her investigate how these cells acquire DNA damage and activate stress response pathways to evade drugs. Understanding these mechanisms could lead to new treatments for cancer.
Fungal infections are rare but deadly, with limited treatment options due to resistance. Developing new antifungals is challenging due to biological similarities between humans and fungi.
Scientists at Far Eastern Federal University have developed a compound that kills prostate cancer cells while also activating an enzyme protecting them. The compound, 3,10-dibromofascaplysin, works well in combination with approved anticancer drugs and is being studied for its potential to reduce side effects.
Researchers identified various molecular pathways and predictive biomarkers of drug resistance in diffuse large B-cell lymphoma. Tailored therapies can improve prognosis for patients with refractory disease, particularly those with specific clinical features.
Researchers identified key risk genes associated with schizophrenia and their impact on antipsychotic medication efficacy. Examining these single nucleotide polymorphisms (SNPs) can help differentiate between responsive and treatment-resistant patients.
Researchers at UT Southwestern Medical Center have discovered that a combination of three decades-old antibiotics can block pain triggered by nerve damage. The finding offers an alternative to opioid-based painkillers and could potentially treat chronic pain caused by damaged nerves.
A new approach inhibiting SCD and blocking FOSB function blunts acquired resistance and extends survival in mouse models of glioblastoma, with potential applicability to other cancers like melanoma.
A team of veterinarians from RUDN University tested a complex preparation called gentaminoseleferon to treat respiratory infection in calves. The study showed that the treatment reduced inflammatory processes and promoted active recovery of metabolism, indicating its therapeutic efficiency.
A new study from Boston University School of Medicine has discovered a drug that can inhibit the growth and spread of melanoma in human cells and experimental models. The researchers found that this drug acts through a specific pathway to prevent cancer cell growth and metastasis.
A recent study discovered that SORLA protein plays a crucial role in the growth of breast cancer cells in the brain and their resistance to HER2 therapy. Removing SORLA from cancer cells sensitizes them to anti-HER2 treatment, offering new possibilities for targeting drug-resistant cancers.
Researchers have identified a promising therapeutic combination for renal cell carcinoma, utilizing ACE2 expression analysis. The study found that higher ACE2 expression correlates with better overall survival in patients with RCC.
Researchers propose a new TB drug targeting the FtsZ protein, inhibiting cell division and suppressing growth, with potential for long-term effectiveness. The compound has been identified through high-precision molecular simulations, offering a novel solution to the problem of drug resistance in TB.
Researchers at Duke-NUS Medical School have designed armoured immune cells that can target hepatocellular carcinoma, a common type of primary liver cancer, without being affected by immunosuppressive drugs used to prevent organ rejection. The T cells remain effective for up to four days before regaining sensitivity to the drugs.
Scientists at Wits University infected mosquitoes with human malaria and identified a new chemical compound that shows promise in treating the disease. The study, published in Nature Communications, aimed to develop a drug that can block both human-to-mosquito transmission and mosquito-to-human transmission.
A new study published in Sports Medicine finds that resistance training has similar benefits for older women and men, with women achieving greater relative increases in lower body strength. The research suggests that trainers should program differently for each sex to maximize training benefits.
Researchers discover new mutations in malaria parasite that enhance resistance to sulfadoxine-pyrimethamine, a key preventive drug. These mutations are already widespread in Africa and Asia, threatening efforts to use the drug to prevent malaria in vulnerable groups.
Researchers found that chromothripsis breaks up chromosomes, leading to the formation of rearranged genomes and extra-chromosomal DNA that promotes cancer cell growth and drug resistance. This phenomenon enables cancer cells to evade treatment and become more aggressive.
Researchers have discovered that free-floating circular DNA fragments called ecDNA form in cancer cells and drive gene amplification to generate drug resistance. Combining chemotherapeutic drugs with molecules that prevent ecDNA formation can inhibit its emergence and reduce drug resistance.
Researchers found that reduced amounts of p120ctn contribute to resistance in cancers with high EGFR levels, leading to poorer treatment outcomes. Testing for p120ctn levels may help clinicians identify patients at risk for therapy resistance or relapse.
Researchers at Cincinnati Children's Hospital Medical Center have discovered a novel method to boost the effectiveness of mTOR inhibitors against acute myeloid leukemia (AML) by targeting alternative signaling pathways. The study suggests using a combination therapy that combines an mTOR inhibitor with other drugs inhibiting CDK9, c-My...
A subcutaneous injection of teclistamab elicits responses in 74% of patients with relapsed/refractory multiple myeloma, offering a promising treatment option for patients with poor prognoses. The study's results suggest that teclistamab takes a similar approach to cellular therapies but is more convenient and faster to administer.
New research suggests that dolutegravir, a widely used 'wonder drug' for HIV treatment, may not be as effective in patients with resistant strains of the virus. The study found that individuals with efavirenz-resistant mutations were less likely to achieve viral suppression when treated with dolutegravir.
Researchers at Charité and Tel Aviv University are investigating the causes of drug tolerance in invasive fungal pathogens. They aim to identify molecular pathways that explain this phenomenon and develop new treatments for life-threatening fungal infections.
A new University of Colorado Boulder study sheds light on CDK7's role in controlling cell growth and transcription, potentially leading to new therapies for hard-to-treat cancers and rare developmental disorders. The findings suggest that CDK7 inhibitors could have distinct therapeutic advantages and result in more selective and less d...
Purdue University engineers have developed a microfluidic device that allows scientists to test drugs on multiple tumor cell subtypes, revealing new insights into drug resistance. The technology mimics the behavior of pancreatic cancer cells within a tumor, enabling researchers to identify effective treatment strategies.
Researchers have developed a new cancer-specific anticancer drug that can prevent drug resistance and reduce side effects. The drug is designed to release an anticancer agent along with a drug-resistance inhibitor in cancer cells, effectively treating cancers without recurrence or treatment failure.
Researchers from RUDN University have developed a novel domino reaction for synthesizing chromenoisoquinolineamine derivatives, which showed promising antitumor activity against cancer cells, including drug-resistant strains. The new compounds were found to be toxic to tumor cells and efficient even at low concentrations.
A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab. In a non-Hodgkin's lymphoma mouse model, the treatment substantially increased rituximab binding and antibody-dependent cellular cytotoxicity activity, resulting in significant tumor growth delay.
Researchers have developed a new hyperpolarisation technique to monitor cancer drug efficacy, potentially replacing tissue biopsies. The method detects biomarkers like FOXM1, indicating drug resistance in ER-positive breast cancer.
Researchers at the University of Pittsburgh have discovered 'repliclones', large clones of HIV-infected cells that produce infectious virus particles, which can cause persistent viremia despite adherence to therapy. This finding has significant clinical implications and highlights a key barrier to developing a true cure for HIV.
A new potential drug treatment has been discovered for a type of lung-cancer. Researchers have found that combining osimertinib with linsitinib can cure or delay tumor recurrence in EGFR-mutated lung cancer, even in AXL-low expressing tumors.
A Duke University-led team has discovered how malaria parasites can survive fevers by producing a special lipid molecule and binding to heat shock proteins. This could lead to new ways to fight resistant strains of the disease. The findings also suggest caution when using fever reducers with artemisinin-based compounds.
Scientists at UT Austin identified a protein that promotes DNA damage in BRCA 1/2-mutated cancer cells, making them resistant to PARP inhibitors. The finding may help create more effective treatment plans for patients with these cancers.
Hundreds of thousands of UK patients are self-medicating with illegal cannabis-based products due to limited prescription availability. Researchers found that concerns about a perceived lack of scientific evidence and resistance from the medical profession hinder prescribing, despite substantial evidence of effectiveness in various dis...
A recent study examined the pharmacist's role in HIV care in France, revealing that only 40% of pharmacists systematically offer online patient medication files to people living with HIV. The survey also found that 7% of those who were offered medication interviews felt well taken care of.
Researchers at USP and UNICAMP discovered eight novel polyphenols with anti-cancer properties in Brazilian red propolis. Two substances isolated from the rarest type of propolis significantly reduced proliferation of ovarian, breast, and brain cancer cells.
Scientists from the University of Edinburgh have made a groundbreaking discovery that fungal cells can develop drug resistance through epigenetic changes, without altering their DNA sequence. This finding has the potential to revolutionize the management of fungal infections in plants and humans.
Researchers developed a novel drug delivery system that significantly enhances the effectiveness of treatment for melanoma. The system uses a biocompatible and biodegradable polymer to deliver two proven medications simultaneously at the tumor site, resulting in longer-lasting therapeutic effects and lower dosages.
Researchers used magnetic resonance elastography to detect changes in the hippocampus of patients with mesial temporal lobe epilepsy, which is resistant to medication. The study found that MRE can improve early detection and characterization of the disease.
Researchers have identified the human immune system's Achilles heel for a new, effective drug against Candida auris. The fungus is especially dangerous for people with compromised immunity and can be resistant to many disinfectants and fungicides.
Researchers adapted principles of quantum control to calculate alternative interventions for infection and cancer. They developed a mathematical algorithm that can design and speed up specific interventions to prevent or overturn drug resistance, offering a promising approach to defeating drug-resistant diseases.
Researchers at Children's Hospital of Philadelphia have developed a new treatment that shows long-term remissions in 80% to 100% of mice with drug-resistant or high-risk solid tumors. The treatment is less toxic than conventional chemotherapy, with fewer side effects.
A team of researchers at the Medical University of South Carolina has identified a critical player in resistance to targeted therapy in lung cancer. The protein NRP2b was found to drive resistance in non-small cell lung cancer cells that had become resistant to therapy, and inhibiting it caused the death of these cells.
Scientists developed an injectable HIV drug that blocks infection and provides extended viral suppression with lower doses and reduced side effects. The drug, CPT31, has great potential to help patients with drug resistance and those who would benefit from a longer-acting treatment option.
A new study suggests that repurposing cancer drugs to target human enzymes could lead to effective treatments for COVID-19, while reducing the risk of drug resistance. This approach has the potential to save years of research and millions of dollars in development costs.
A new computational model called TransComp-R has been developed to improve the translation of drugs from animal studies to human clinical trials. The model identified an overlooked biological mechanism possibly responsible for a patient's resistance to infliximab, a drug for inflammatory bowel diseases.
Researchers have discovered a new broad-spectrum method to treat human herpes viruses by targeting their physical properties rather than proteins. This approach prevents genes from leaving the virus and infecting cells, making it effective against resistant strains.
Researchers developed a stable 'mirror-image' peptide that effectively blocks the interaction between TIGIT and its ligand PVR, inhibiting tumor growth and metastasis. This approach offers an alternative point of attack for cancer immunotherapy, potentially outperforming existing anti-PD-1 therapy.
Researchers found that a low-dose combination of four inhibitors is more effective in treating NSCLC with EGFR mutation. The therapy, called MLD, inhibits the action of multiple proteins in the same signaling pathway, blocking cell proliferation and tumor growth.
Researchers discovered resistance to tumor inhibitors arises from gradual adaptation to selective pressures, providing opportunity for effective therapies. The study advances in evolution of resistance and offers evolutionary-informed therapies for future treatments.
Researchers analyzed 442 AML samples to identify immune classes that predict drug resistance and response to immunotherapy. IFN-γ-dominant AML patients showed strong responses to flotetuzumab and improved survival rates, highlighting the potential for T cell-targeting therapies.
Myeloma Drug Sensitivity Testing (My-DST) uses liquid biopsies to test drug effectiveness on patient samples. The approach shows promise in predicting real patient responses, and may guide drug development for multiple myeloma treatment.
Researchers at UCLA Jonsson Comprehensive Cancer Center found that combining toll-like receptor 9 agonists and NKTR-214 with PD-1 blockade can induce a potent immune reaction against resistant tumors. This combination therapy is being assessed in human clinical trials to improve cancer immunotherapy outcomes.